Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.

N, Nakagawa; Y, Murakami; K, Uemura; T, Sudo; Y, Hashimoto; N, Kondo; T, Sueda

doi:10.1016/j.surg.2012.10.010

Public

Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.

Published in Surgery • Dec 17, 2012

Authors:

Nakagawa N

Murakami Y

Uemura K

Abstract

<h4>Background</h4>Although postoperative adjuvant chemotherapy for pancreatic carcinoma improves survival in some patients, its efficacy varies among individuals. The aim of this study was to determine the usefulness of intratumoral expression of human equilibrative nucleoside transporter 1 (hENT1)...

View

Paywalled

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Generate AI Take for this paper

Discussions